U.S. Stock Insider Trading | Gilead Sciences disclosed five insider trading transactions on March 12

K-LinePoet · 2026-04-08T12:26:21+00:00

Gilead Sciences disclosed multiple insider transactions on March 12, 2026, including several executives such as Director O'Day Daniel Patrick selling shares on March 10, involving nearly $2.5 million. Gilead Sciences focuses on developing innovative drugs, committed to addressing unmet medical needs.

K-LinePoet

2026-04-08 12:26:21

Abstract generation in progress

On March 12, 2026, Gilead Sciences (GILD) disclosed five company insider transactions. On March 10, 2026, Director O’Day Daniel Patrick sold 9,767 shares.

【Recent Insider Transactions】

Disclosure Date	Title	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/US$	Total Amount/US$
March 12, 2026	Director	O’Day Daniel Patrick	March 10, 2026	Sold	9767	148.56	90k
March 12, 2026	Executive Officer	Mercier Johanna	March 10, 2026	Sold	3216	148.56	467.5k
March 12, 2026	Executive Officer	Berger Dietmar	March 10, 2026	Sold	1063	148.56	931.9k
March 12, 2026	Executive Officer	Dickinson Andrew D	March 10, 2026	Sold	3147	148.56	477.8k
March 12, 2026	Executive Officer	Cain Wettan Keeley M	March 10, 2026	Sold	606	148.56	1.45M
March 2, 2026	Director	O’Day Daniel Patrick	February 27, 2026	Sold	100	145.71	1.46M
March 2, 2026	Director	O’Day Daniel Patrick	February 27, 2026	Sold	3481	144.04	463.3k
March 2, 2026	Director	O’Day Daniel Patrick	February 27, 2026	Sold	6419	145.18	157.9k
February 18, 2026	Executive Officer	Mercier Johanna	February 17, 2026	Sold	9395	154.91	14.6k
February 18, 2026	Executive Officer	Dickinson Andrew D	February 17, 2026	Sold	3000	154.43	501.4k

【Company Profile】

Gilead Sciences, Inc. was incorporated in Delaware on June 22, 1987. It is a research-based biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines that address unmet medical needs. Its major areas of focus include viral diseases, inflammatory and fibrotic diseases, and oncology.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes